Center-Authored Papers

Filters: Author is Chamberlain, Marc C  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Z
Zairi F, Le Rhun E, Bertrand N, Boulanger T, Taillibert S, Aboukais R, Assaker R, Chamberlain MC.  2015.  Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients.. Journal of neuro-oncology. Abstract
W
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen GA, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB et al..  2010.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(11):1963-72. Abstract
T
Taillibert S, Le Rhun E, Chamberlain MC.  2016.  Chemotherapy-Related Neurotoxicity.. Current neurology and neuroscience reports. 16(9):81. Abstract
Taillibert S, Le Rhun E, Chamberlain MC.  2015.  Tumor treating fields: a new standard treatment for glioblastoma? Current opinion in neurology. 28(6):659-64. Abstract
S
Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY.  2015.  Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.. Cancer. Abstract
Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen P.  2013.  PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY AND PHARMACOKINETICS (PK) OF CABOZANTINIB (XL184) CONCURRENT WITH TEMOZOLOMIDE (TMZ) & RADIATION (RT) OR TMZ POST-RT IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS (HGG). Neuro-Oncology. 15:81–81. Abstract
P
Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ et al..  2014.  Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.. Neuro-oncology. Abstract
Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS et al..  2012.  Initial treatment patterns over time for anaplastic oligodendroglial tumors.. Neuro-oncology. 14(6):761-7. Abstract
N
Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A et al..  2014.  Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(11):1517-23. Abstract
M
Mazbani E, Jones RL, Fink J, Chamberlain MC.  2013.  Delayed development of a rhabdomyosarcoma following radiation for a spinal cord glioma.. Journal of neuro-oncology. Abstract
L
Le Rhun E, Taillibert S, Devos P, Zairi F, Turpin A, Rodrigues I, Cazin JL, Pierret MF, André C, Dubois F et al..  2013.  Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases: a retrospective case series.. Anti-cancer drugs. 24(10):1093-7. Abstract
Le Rhun E, Taillibert S, Chamberlain MC.  2015.  Anaplastic glioma: current treatment and management.. Expert review of neurotherapeutics. :1-20. Abstract
Le Rhun E, Kramar A, Salingue S, Girot M, Rodrigues I, Mailliez A, Zairi F, Bakhache E, Robin YM, Taillibert S et al..  2014.  CSF CA 15-3 in breast cancer-related leptomeningeal metastases.. Journal of neuro-oncology. 117(1):117-24. Abstract
Le Rhun E, Le Rhun E, Taillibert S, Chamberlain MC.  2015.  The future of high-grade glioma: Where we are and where are we going.. Surgical neurology international. 6(Suppl 1):S9-S44. Abstract
Le Rhun E, Taillibert S, Boulanger T, Zairi F, Bonneterre J, Chamberlain MC.  2015.  Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases.. Case reports in oncology. 8(1):72-7. Abstract
Le Rhun E, Taillibert S, Chamberlain MC.  2016.  Current Management of Adult Diffuse Infiltrative Low Grade Gliomas.. Current neurology and neuroscience reports. 16(2):15. Abstract
Le Rhun E, Chamberlain MC, Zairi F, Delmaire C, Idbaih A, Renaud F, Maurage CA, Grégoire V.  2015.  Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients.. CNS oncology. Abstract
Le Rhun E, Taillibert S, Chamberlain MC.  2017.  Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases.. Cancer control : journal of the Moffitt Cancer Center. 24(1):22-32. Abstract
Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS et al..  2012.  Response to Weltman and Fleury Malheiros, re Lassman et al.. Neuro-oncology. 14(6):677-678.
H
Holdhoff M, Chamberlain MC.  2013.  Controversies in the treatment of elderly patients with newly diagnosed glioblastoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(9):1165-72;quiz1173. Abstract
G
Grimm SA, Chamberlain MC.  2015.  Bevacizumab and other novel therapies for recurrent oligodendroglial tumors.. CNS oncology. Abstract
Grimm SA, Chamberlain MC.  2013.  Brainstem glioma: a review.. Current neurology and neuroscience reports. 13(5):346. Abstract
Glantz MJ, Van Horn A, Fisher R, Chamberlain MC.  2010.  Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis.. Cancer. 116(8):1947-52. Abstract
F
Floeter AE, Patel A, Tran M, Chamberlain MC, Hendrie PC, Gopal AK, Cassaday RD.  2017.  Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.. Clinical lymphoma, myeloma & leukemia. Abstract
Fink J, Born D, Chamberlain MC.  2012.  Radiation necrosis: relevance with respect to treatment of primary and secondary brain tumors.. Current neurology and neuroscience reports. 12(3):276-85. Abstract